Trigger Point Injections for Myofascial Pain

Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Arizona
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine how the number of needle passes in trigger point injections affects pain relief and patient satisfaction for individuals with myofascial pain, a condition causing chronic muscle pain. Participants will join one of three groups, receiving either 2, 10, or 20 needle passes in their muscle trigger points. The trial seeks to identify which method provides the best pain relief and improves daily function. Individuals with myofascial pain who have not found relief with other treatments and can communicate in English may be suitable for this study. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that trigger point injections are generally safe for treating muscle pain. Most patients tolerate this procedure well. The injections typically contain a local anesthetic, which numbs the area and reduces discomfort during the procedure.

If side effects occur, they are usually mild, such as temporary soreness or bruising at the injection site. Serious side effects are rare. Some studies note that results can vary, but overall, trigger point injections are considered a safe option for managing pain related to muscle knots.

These injections are already used in medical practice and have a history of safety for many people. However, new studies, including the one under consideration, aim to improve the technique to enhance pain relief and patient satisfaction.12345

Why are researchers excited about this trial?

Researchers are excited about the different needle pass techniques for treating myofascial pain because they offer a potentially more precise way to address trigger points. Unlike standard treatments like physical therapy or medications, this approach directly targets the source of pain with varying intensities. The trial explores the impact of different numbers of needle passes—ranging from one to two, ten, and up to twenty—on pain relief, which could lead to personalized treatment plans. This level of customization could improve efficacy and reduce side effects compared to more generalized treatments.

What evidence suggests that this trial's treatments could be effective for myofascial pain?

Research has shown that trigger point injections can greatly reduce pain and improve movement in individuals with myofascial pain. Studies have found these injections offer better pain relief than standard medical treatments. They are also cost-effective and less invasive, making them a popular choice. This trial will compare different techniques, specifically the number of needle passes, to determine the most effective approach. Participants will receive either one to two needle passes, ten needle passes, or twenty needle passes at each trigger point. Although experts do not fully agree on the optimal number of needle passes, early use of these injections has yielded good results with various techniques. Overall, trigger point injections are considered an effective treatment for myofascial pain.15678

Who Is on the Research Team?

MI

Mohab Ibrahim, Md., Ph.D

Principal Investigator

University of Arizona

Are You a Good Fit for This Trial?

This trial is for English-speaking individuals with myofascial pain who haven't found relief through conservative treatments or can't do physical therapy. It's not suitable for those with serious mental illnesses that affect pain perception or conditions causing widespread pain.

Inclusion Criteria

I have been diagnosed with muscle pain.
Able to speak, read and write English
Physical therapy did not work for me or I cannot do it.

Exclusion Criteria

I have a history of conditions that cause widespread pain.
I have a mental illness that affects my ability to feel changes in pain.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive trigger point injections with varying needle passes (2, 10, or 20) based on randomization

1 day
1 visit (in-person)

Follow-up

Participants are monitored for changes in pain intensity, sleep patterns, and functional abilities over 60 days

8 weeks
Regular follow-up assessments

What Are the Treatments Tested in This Trial?

Interventions

  • Trigger Point Injection
Trial Overview The study tests how many needle passes in trigger point injections (using lidocaine and bupivacaine) are best for relieving chronic muscle pain. Participants will be randomly assigned to receive either 2, 10, or 20 needle passes at a clinic in Tucson, Arizona.
How Is the Trial Designed?
3Treatment groups
Active Control
Group I: One to two needle passesActive Control1 Intervention
Group II: Ten needle passesActive Control1 Intervention
Group III: Twenty needle passesActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Arizona

Lead Sponsor

Trials
545
Recruited
161,000+

Published Research Related to This Trial

Trigger point injection (TPI) is considered a safe procedure for treating chronic non-malignant musculoskeletal pain, particularly for conditions like head, neck, shoulder, and back pain, when performed by trained clinicians.
While TPI can relieve symptoms and may enhance outcomes when combined with other therapies, the overall evidence for its efficacy remains inconclusive, with no definitive benefits established compared to other treatment options.
Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review.Scott, NA., Guo, B., Barton, PM., et al.[2022]

Citations

Trigger Point Injections Versus Medical Management for ...Several studies indicate that trigger point injections yield substantial pain relief and enhance functional outcomes [29,30].
Current advances in the treatment of myofascial pain ...This method is low cost and less invasive, and early clinical applications have shown good efficacy. In this paper, we have reviewed clinical ...
Trigger Point Injection for Myofascial Pain Syndrome of the ...The primary outcome was change in pain at 30 to 60 minutes measured on a 10 cm visual analog scale. Secondary outcomes included changes in the ...
Trigger Point ManagementA statistically significant improvement in pain-pressure threshold was observed over the trapezius and suboccipital muscles in the massage-treated group, ...
Trigger Point Injection for Myofascial Pain Syndrome in the ...This will be the first TPI study to compare ST, to TPI with local anesthetic, and TPI with NS for LBP conducted in an ED.
Trigger Point Injection - StatPearls - NCBI BookshelfTreating pain with a multimodal approach is paramount in providing safe and effective results for patients. Trigger point injections can be an effective primary ...
Trigger point injection therapies for chronic myofascial ...Pain, functional outcomes, and harms were extracted. Outcome time points were divided into short term (7 days to <6 weeks), intermediate term (6 weeks to ​< ​3 ...
LCD - Trigger Point Injections (TPI) (L39656)Trigger point injections have been described as an overall safe and effective modality for the treatment of pain associated with myofascial trigger points.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security